Drug intelligence / Profile preview

AB3000

Development stage: Preclinical
Lead developer: Alveolus Biomedical
Modality: Small Molecules
Administration: Inhalation

Overview

AB3000 is a preclinical-stage small molecule therapeutic being developed by Alveolus Biomedical for the treatment of Pulmonary Arterial Hypertension (PAH). As part of Alveolus Biomedical's focus on inhaled therapies for severe respiratory and pulmonary vascular diseases, AB3000 is designed for delivery directly to the lungs. While the specific molecular target has not been publicly disclosed, the program aims to address the underlying pathophysiology of PAH, a progressive condition characterized by high blood pressure in the lung arteries and vascular remodeling.

Beyond the preview

Go deeper on AB3000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB3000.

Explore the full profile